Acute doxorubicin (DOX) cardiotoxicity can be attenuated by exercise preconditioning, but little is known of whether this cardioprotection continues beyond 10 days post-DOX administration. The purpose of this study was to determine the effects of exercise preconditioning on early chronic DOX-induced cardiotoxicity. Male rats were randomly assigned to sedentary, treadmill, or wheel running groups. Treadmill and wheel running animals participated in a progressive treadmill training protocol or voluntary wheel running, respectively, for 10 weeks. Following the intervention, animals were further randomized to receive either DOX (sedentary + DOX, treadmill + DOX, wheel running + DOX) or saline (sedentary + saline, treadmill + saline, wheel running + saline). All animals then remained sedentary for 4 weeks. A 22% reduction in fractional shortening was observed in left ventricles from previously sedentary animals receiving DOX when compared with sedentary + saline. This degree of decline was not observed in treadmill + DOX and wheel running + DOX. Sedentary + DOX possessed significantly depressed mitral and aortic valve blood flow velocities when compared with sedentary + saline, but these decrements were not observed in treadmill + DOX and wheel running + DOX. Ex vivo analysis revealed that left ventricular developed pressure and maximal rate of pressure development were significantly lower in sedentary + DOX when compared to sedentary + saline. Treadmill and wheel running prior to DOX treatment protected against these decrements. Exercise cardioprotection was associated with preserved myosin heavy chain but not sarcoendoplasmic reticulum Ca2+ ATPase 2a expression. In conclusion, 10 weeks of prior exercise protected against early chronic DOX cardiotoxicity suggesting that training status may be a determining factor in the degree of late-onset cardiotoxicity experienced by cancer patients undergoing treatment with DOX.
Bernstein D. , Fajardo G., Zhao M., et al. Differential cardioprotective/cardiotoxic effects mediated by beta-adrenergic receptor subtypes. Am J Physiol Heart Circ Physiol. 2005;289:H2441-H2449.
2.
Chicco AJ, Schneider CM, Hayward R.Exercise training attenuates acute doxorubicin-induced cardiac dysfunction . J Cardiovasc Pharmacol. 2006;47:182-189.
3.
Hydock DS, Lien CY, Schneider CM, Hayward R.Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction . Med Sci Sports Exerc. 2008;40:808-817.
4.
Lipshultz SE , Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia . J Clin Oncol. 2005;23:2629-2636.
5.
Simunek T., Sterba M., Popelova O., Adamcova M., Hrdina R., Gersl V.Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep . 2009;61:154-171.
6.
Arnolda L., McGrath B., Cocks M., Sumithran E., Johnston C.Adriamycin cardiomyopathy in the rabbit: an animal model of low output cardiac failure with activation of vasoconstrictor mechanisms. Cardiovasc Res. 1985;19:378-382.
7.
Hayward R., Hydock DSDoxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci. 2007;46:20-32.
8.
Cole MP, Chaiswing L., Oberley TD, et al. The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity. Cardiovasc Res. 2006;69:186-197.
9.
Alyane M., Kebsa LB, Boussenane HN, Rouibah H., Lahouel M.Cardioprotective effects and mechanism of action of polyphenols extracted from propolis against doxorubicin toxicity. Pak J Pharm Sci . 2008;21:201-209.
10.
Hydock DS, Lien CY, Hayward R.Anandamide preserves cardiac function and geometry in an acute doxorubicin cardiotoxicity rat model. J Cardiovasc Pharmacol Ther. 2009;14:59-67.
11.
Ramond A., Sartorius E., Mousseau M., Ribuot C., Joyeux-Faure M.Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts. Exp Biol Med (Maywood ). 2008;233:76-83.
12.
Cusack BJ, Gambliel H., Musser B., et al. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism. Cancer Chemother Pharmacol. 2006;58:517-526.
13.
Tesoriere L., Ciaccio M., Valenza M., et al. Effect of vitamin A administration on resistance of rat heart against doxorubicin-induced cardiotoxicity and lethality. J Pharmacol Exp Ther. 1994;269:430-436.
14.
Berthiaume JM , Oliveira PJ, Fariss MW, Wallace KBDietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction. Cardiovasc Toxicol. 2005;5:257-267.
15.
Riad A., Bien S., Westermann D., et al. Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice. Cancer Res. 2009;69:695-699.
16.
Chao HH, Liu JC, Hong HJ, Lin JW, Chen CH, Cheng THL-carnitine reduces doxorubicin-induced apoptosis through a prostacyclin-mediated pathway in neonatal rat cardiomyocytes [published online ahead of print June 24, 2009]. Int J Cardiol. doi:10.1016/j.ijcard.2009.06.010.
Abu-Khalaf MM, Juneja V., Chung GG, et al. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer. Breast Cancer Res Treat. 2007;104:341-349.
19.
Pein F., Sakiroglu O., Dahan M., et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy . Br J Cancer. 2004;91:37-44.
20.
Quiles JL, Huertas JR, Battino M., Mataix J., Ramirez-Tortosa MCAntioxidant nutrients and adriamycin toxicity. Toxicology . 2002;180:79-95.
21.
Hydock DS, Wonders KY, Schneider CM, Hayward R.Voluntary wheel running in rats receiving doxorubicin: effects on running activity and cardiac myosin heavy chain. Anticancer Res. 2009;29:4401-4407.
22.
de Beer EL, Bottone AE, van Der Velden J., Voest EEDoxorubicin impairs crossbridge turnover kinetics in skinned cardiac trabeculae after acute and chronic treatment. Mol Pharmacol. 2000;57:1152-1157.
23.
Herron TJ, Korte FS, McDonald KSLoaded shortening and power output in cardiac myocytes are dependent on myosin heavy chain isoform expression. Am J Physiol Heart Circ Physiol . 2001;281:H1217-H1222.
24.
Maeda A., Honda M., Kuramochi T., Takabatake T.A calcium antagonist protects against doxorubicin-induced impairment of calcium handling in neonatal rat cardiac myocytes. Jpn Circ J. 1999;63:123-129.
25.
Mijares A., Lopez JRL-carnitine prevents increase in diastolic [Ca2+] induced by doxorubicin in cardiac cells. Eur J Pharmacol. 2001;425:117-120.
26.
Olson RD, Gambliel HA, Vestal RE, Shadle SE, Charlier HA Jr, Cusack BJDoxorubicin cardiac dysfunction: effects on calcium regulatory proteins, sarcoplasmic reticulum, and triiodothyronine. Cardiovasc Toxicol. 2005;5:269-283.
27.
Arai M., Yoguchi A., Takizawa T., et al. Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)ATPase gene transcription. Circ Res. 2000;86:8-14.
28.
Kanter MM, Hamlin RL, Unverferth DV, Davis HW, Merola AJEffect of exercise training on antioxidant enzymes and cardiotoxicity of doxorubicin . J Appl Physiol. 1985;59:1298-1303.
29.
Chicco AJ, Hydock DS, Schneider CM, Hayward R.Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity. J Appl Physiol. 2006; 100:519-527.
30.
Talmadge RJ , Roy RRElectrophoretic separation of rat skeletal muscle myosin heavy-chain isoforms. J Appl Physiol. 1993;75:2337-2340.
31.
Bradford MMA rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
32.
Aragno M., Mastrocola R., Medana C., et al. Oxidative stress-dependent impairment of cardiac-specific transcription factors in experimental diabetes. Endocrinology. 2006;147:5967-5974.
33.
French JP, Quindry JC, Falk DJ, et al. Ischemia-reperfusion-induced calpain activation and SERCA2a degradation are attenuated by exercise training and calpain inhibition. Am J Physiol Heart Circ Physiol. 2006;290:H128-H136.
34.
Emter CA, McCune SA, Sparagna GC, Radin MJ, Moore RLLow-intensity exercise training delays onset of decompensated heart failure in spontaneously hypertensive heart failure rats. Am J Physiol Heart Circ Physiol. 2005;289:H2030-H2038.
35.
Edes IF, Toth A., Csanyi G., et al. Late-stage alterations in myofibrillar contractile function in a transgenic mouse model of dilated cardiomyopathy (Tgalphaq*44). J Mol Cell Cardiol. 2008;45:363-372.
36.
Zhong Y., Reiser PJ, Matlib MAGender differences in myosin heavy chain-beta and phosphorylated phospholamban in diabetic rat hearts. Am J Physiol Heart Circ Physiol. 2003;285:H2688-H2693.
37.
Krenz M., Sanbe A., Bouyer-Dalloz F., et al. Analysis of myosin heavy chain functionality in the heart. J Biol Chem. 2003;278:17466-17474.
38.
Korte FS, Herron TJ, Rovetto MJ, McDonald KSPower output is linearly related to MyHC content in rat skinned myocytes and isolated working hearts. Am J Physiol Heart Circ Physiol. 2005;289:H801-H812.
39.
Herron TJ, McDonald KSSmall amounts of alpha-myosin heavy chain isoform expression significantly increase power output of rat cardiac myocyte fragments. Circ Res. 2002;90:1150-1152.
40.
Tardiff JC, Hewett TE, Factor SM, Vikstrom KL, Robbins J., Leinwand LAExpression of the beta (slow)-isoform of MHC in the adult mouse heart causes dominant-negative functional effects. Am J Physiol Heart Circ Physiol. 2000; 278:H412-H419.
41.
Oliveira PJ , Wallace KBDepletion of adenine nucleotide trans-locator protein in heart mitochondria from doxorubicin-treated rats-relevance for mitochondrial dysfunction. Toxicology. 2006 ;220:160-168.
42.
Morris GS, Prevost MC, Nelson AGMorderate diabetes alters myosin isoenzyme distribution in cardiac but not skeletal muscle of male rats. Life Sci. 1996 ;58:833-838.
43.
Nousiainen T. , Jantunen E., Vanninen E., Hartikainen J.Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002;86:1697-1700.
44.
Konorev EA, Vanamala S., Kalyanaraman B.Differences in doxorubicin-induced apoptotic signaling in adult and immature cardiomyocytes. Free Radic Biol Med. 2008; 45:1723-1728.
45.
Ueno M., Kakinuma Y., Yuhki K., et al. Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J Pharmacol Sci. 2006;101:151-158.
46.
Jang YM, Kendaiah S., Drew B., et al. Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats. FEBS Lett . 2004;577:483-490.
47.
Zhang YW, Shi J., Li YJ, Wei L.Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz). 2009 ;57:435-445.
48.
Park KH, Kim SY, Gul R., et al. Fatty acids ameliorate doxorubicin-induced intracellular Ca2+ increase and apoptosis in rat cardiomyocytes. Biol Pharm Bull . 2008;31:809-815.
49.
Kim SY, Kim SJ, Kim BJ, et al. Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes. Exp Mol Med. 2006;38:535-545.
50.
Takaseya T. , Ishimatsu M., Tayama E., Nishi A., Akasu T., Aoyagi S.Mechanical unloading improves intracellular Ca2+ regulation in rats with doxorubicin-induced cardiomyopathy. J Am Coll Cardiol. 2004;44:2239-2246.
51.
Corapcioglu F., Sarper N., Berk F., Sahin T., Zengin E., Demir H.Evaluation of anthracycline-induced early left ventricular dysfunction in children with cancer: a comparative study with echocardiography and multigated radionuclide angiography. Pediatr Hematol Oncol. 2006;23:71-80.
52.
Iarussi D., Pisacane C., Indolfi P., Casale F., Martino V., Di Tullio MTEvaluation of left ventricular function in long-term survivors of childhood Hodgkin disease. Pediatr Blood Cancer. 2005 ;45:700-705.
53.
Chicco AJ, Schneider CM, Hayward R.Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart. Am J Physiol Regul Integr Comp Physiol. 2005;289:R424-R431.
54.
Ascensao A. , Magalhaes J., Soares J., et al. Endurance training attenuates doxorubicin-induced cardiac oxidative damage in mice. Int J Cardiol. 2005;100:451-460.
55.
Jin H., Yang R., Li W., et al. Effects of exercise training on cardiac function, gene expression, and apoptosis in rats. Am J Physiol Heart Circ Physiol. 2000;279:H2994-H3002.
56.
Dudnakova TV , Lakomkin VL, Tsyplenkova VG, Shekhonin BV, Shirinsky VP, Kapelko VIAlterations in myocardial cytoskeletal and regulatory protein expression following a single doxorubicin injection. J Cardiovasc Pharmacol. 2003;41:788-794.
57.
Andersson KB , Birkeland JA, Finsen AV, et al. Moderate heart dysfunction in mice with inducible cardiomyocyte-specific excision of the Serca2 gene. J Mol Cell Cardiol. 2009;47:180-187.
58.
Barry WHMolecular inotropy: a future approach to the treatment of heart failure? Circulation. 1999;100:2303-2304.
59.
Mayosi BM, Kardos A., Davies CH, et al. Heterozygous disruption of SERCA2a is not associated with impairment of cardiac performance in humans: implications for SERCA2a as a therapeutic target in heart failure. Heart. 2006;92:105-109.
60.
Lu L., Mei DF, Gu AG, et al. Exercise training normalizes altered calcium-handling proteins during development of heart failure. J Appl Physiol. 2002;92:1524-1530.
61.
Shao CH, Wehrens XH, Wyatt TA, et al. Exercise training during diabetes attenuates cardiac ryanodine receptor dysregulation. J Appl Physiol. 2009 ;106:1280-1292.
62.
Noble EG, Moraska A., Mazzeo RS, et al. Differential expression of stress proteins in rat myocardium after free wheel or treadmill run training. J Appl Physiol . 1999;86:1696-1701.
